These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 30100231)

  • 1. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
    Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O
    Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
    Reig A; Sesé P; Parés A
    Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additional fibrate treatment in UDCA-refractory PBC patients.
    Chung SW; Lee JH; Kim MA; Leem G; Kim SW; Chang Y; Lee HY; Yoon JS; Park JY; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH
    Liver Int; 2019 Sep; 39(9):1776-1785. PubMed ID: 31162879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
    Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
    Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
    Duan W; Ou X; Wang X; Wang Y; Zhao X; Wang Q; Wu X; Zhang W; Ma H; You H; Jia J
    Rev Esp Enferm Dig; 2018 Sep; 110(9):557-563. PubMed ID: 29739227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
    Mitchell SA; Bansi DS; Hunt N; Von Bergmann K; Fleming KA; Chapman RW
    Gastroenterology; 2001 Oct; 121(4):900-7. PubMed ID: 11606503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of fibrates in cholestatic liver diseases.
    Carrion AF; Lindor KD; Levy C
    Liver Int; 2021 Jun; 41(6):1335-1343. PubMed ID: 33751787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis.
    Zhang H; Li S; Feng Y; Zhang Q; Xie B
    Clin Exp Med; 2023 Sep; 23(5):1741-1749. PubMed ID: 36318376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.
    Ding D; Ren P; Guo G; Liu Y; Yang C; Zheng L; Jia G; Deng J; Sun R; Wang X; Zhou X; Shang Y; Han Y
    Gastroenterol Hepatol; 2023 Nov; 46(9):692-701. PubMed ID: 36632973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.
    Lindström L; Hultcrantz R; Boberg KM; Friis-Liby I; Bergquist A
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):841-6. PubMed ID: 23353641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.
    Cheung AC; Lapointe-Shaw L; Kowgier M; Meza-Cardona J; Hirschfield GM; Janssen HL; Feld JJ
    Aliment Pharmacol Ther; 2016 Jan; 43(2):283-93. PubMed ID: 26559762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial.
    Hatami B; Mosala M; Hassani AH; Ardakani MJE; Gholami S; Zali MR
    Pharmacol Res Perspect; 2022 Aug; 10(4):e00984. PubMed ID: 35822553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
    Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
    Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis.
    Soret PA; Lam L; Carrat F; Smets L; Berg T; Carbone M; Invernizzi P; Leroy V; Trivedi P; Cazzagon N; Weiler-Normann C; Alric L; Rosa-Hezode I; Heurgué A; Cervoni JP; Dumortier J; Potier P; Roux O; Silvain C; Bureau C; Anty R; Larrey D; Levy C; Pares A; Schramm C; Nevens F; Chazouillères O; Corpechot C
    Aliment Pharmacol Ther; 2021 May; 53(10):1138-1146. PubMed ID: 33764590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.
    Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL
    J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
    Holtmeier J; Leuschner U
    Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid.
    Lens S; Leoz M; Nazal L; Bruguera M; Parés A
    Liver Int; 2014 Feb; 34(2):197-203. PubMed ID: 23998489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?
    van Milligen de Wit AW; Kuiper H; Camoglio L; van Bracht J; Jones EA; Tytgat GN; van Deventer SJ
    Eur J Gastroenterol Hepatol; 1999 Feb; 11(2):129-36. PubMed ID: 10102223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
    Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
    J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.